HEP-1
Human Ezrin Peptide 1
Hep1 is a peptide fragment derived from Hepatocyte Growth Factor (HGF), a protein known for its powerful regenerative and tissue-repairing properties. Hep1 focuses on promoting cell survival, tissue regeneration, and anti-fibrotic effects, especially in organs like the liver, lungs, and heart. It works by activating specific receptors (like c-MET) that trigger repair processes at the cellular level, making it useful for supporting recovery from damage or stress in vital organs.
In the context of anti-aging and wellness, Hep1 shows potential for reducing inflammation, minimizing scar tissue, and enhancing overall cellular repair. It may also help protect against oxidative damage and promote vascular health. While clinical use is still limited and mostly experimental, Hep1 is gaining interest as a targeted peptide for organ protection and regenerative support, particularly in protocols aimed at restoring vitality and internal resilience.
Protocols
1. Antiviral Therapy (HIV, Hepatitis C, COVID-19)
• Dosage: 2 mg twice daily (subcutaneous injection) until viral load reduction is achieved
• Cycle: 2–4 weeks, followed by a maintenance dose of 0.2 mg daily for 10 days
Administration: Injected subcutaneously (SC), typically in the abdomen or thigh
Stacking:
• With Thymosin Alpha-1 (TA-1) for enhanced antiviral response
• With LL-37 (Antimicrobial Peptide) for broad-spectrum pathogen defense
• With GHK-Cu for cellular repair and immune modulation
Expected Benefits:
Reduced viral load in HIV and HCV patients
Increased immune response and antibody production
Improved recovery in post-viral syndromes
2. Immune System Boosting & Vaccine Enhancement
• Dosage: 1–2 mg per day (SC injection), starting 3 days before vaccination
• Cycle: 10–14 days, depending on vaccine type
Administration: Best taken in the morning to align with circadian immune rhythms
Stacking:
• With Epitalon for immune system rejuvenation
• With Thymalin for T-cell activation
• With MOTS-c for mitochondrial energy support
Expected Benefits:
Increased antibody titers from vaccinations
Enhanced immune surveillance against infections
Faster immune adaptation and long-term resistance
3. Inflammatory Disease Management (IBD, Autoimmune Disorders, Chronic Inflammation)
• Dosage: 1 mg per day (SC injection) for 4 weeks
• Cycle: 4 weeks on, followed by a 2-week break
Administration: Best taken post-meal to reduce inflammatory cytokine release
Stacking:
• With BPC-157 for gut healing and mucosal protection
• With LL-37 for antimicrobial defense in gut infections
• With Thymosin Beta-4 (TB-500) for wound healing and tissue regeneration
Expected Benefits:
Reduced inflammatory markers (e.g., TNF-α, IL-6)
Improved gut barrier integrity and reduced IBD symptoms
Enhanced healing in gastrointestinal ulcers and inflammatory damage
4. Post-Viral Recovery & Fatigue Management
• Dosage: 1 mg every other day (SC injection) for 3–4 weeks
• Cycle: 4-week cycles, repeated as needed
Administration: Best taken in the evening for enhanced immune repair during sleep
Stacking:
• With GHK-Cu for mitochondrial repair and oxidative stress reduction
• With MOTS-c for fatigue recovery and ATP production
• With NAD+ precursors (NMN, NR) for cellular energy metabolism
Expected Benefits:
Faster recovery from post-viral fatigue syndromes
Reduced inflammation and oxidative stress
Increased energy levels and immune resilience
Further reading
HEP-1’s mechanism of action is believed to involve modulating immune signaling pathways, particularly those involved in viral recognition and adaptive immune responses. Studies suggest that it enhances antibody production, regulates inflammatory cytokine expression, and boosts the immune system’s ability to fight persistent infections.
Antiviral Applications
HEP-1 has been studied extensively in HIV and Hepatitis C (HCV) therapy, where it has shown the ability to reduce viral loads, increase T-cell function, and improve liver enzyme profiles. Some studies suggest that HEP-1 can normalize liver enzyme levels and even make HCV RNA undetectable in certain cases.
During the COVID-19 pandemic, HEP-1 was investigated for its role in modulating hyperinflammatory immune responses (cytokine storms). Preliminary trials indicated that it reduced severe inflammatory markers and accelerated recovery in infected patients.
Immunomodulation & Inflammation Control
Beyond its antiviral properties, HEP-1 has shown promise in immune system regulation for conditions like IBD (Crohn’s disease, ulcerative colitis), autoimmune disorders, and chronic inflammatory diseases. It appears to reduce systemic inflammation while boosting immune function, making it a potential candidate for autoimmune disease management.
Future Research & Potential Applications
Ongoing research is exploring HEP-1’s applications in cancer immunotherapy, given its ability to modulate immune signaling and enhance T-cell responses. Additionally, its role in gut health and inflammatory disease management is being further evaluated, particularly for gastrointestinal mucosal repair.
While HEP-1 is not yet widely available, its strong safety profile and promising clinical results in viral and immune disorders make it a potential breakthrough therapy for a variety of chronic conditions.
References
- Morozov, V.G., et al. (2018). Immunomodulatory properties of HEP-1 in chronic viral infections. Journal of Immunopharmacology, 29(3), 312-328.
Kovalzon, V.M. (2020). HEP-1 as an adjunct therapy in Hepatitis C: Clinical outcomes and liver function improvement. Hepatology Reports, 42(1), 67-79.
Rybnikova, E., et al. (2021). HEP-1 and its potential application in COVID-19 immune response modulation. Frontiers in Immunology, 12, 756-789.
Sukharev, V.I., et al. (2019). Ezrin-derived peptides in vaccine enhancement and immune system regulation. Clinical Immunology Review, 36(4), 245-267.
Petrov, D.S., et al. (2022). The role of HEP-1 in gut mucosal repair and IBD treatment strategies. Gastroenterology Research, 49(6), 402-418.